Aachen \u2014 The \u201cSeed Fonds II f\u00fcr die Region Aachen GmbH & Co. KG\u201d (Seed Fonds Aachen), toge\u00adther with KfW Banken\u00adgruppe, Qiagen co-foun\u00adder Dr. J\u00fcrgen Schu\u00adma\u00adcher and Dr. Robert Huber, Profes\u00adsor of Biopro\u00adcess Engi\u00adnee\u00adring, have sold their shares in the Aachen-based start-up aquila biolabs GmbH to Scien\u00adti\u00adfic Biopro\u00adces\u00adsing, Inc. (SBI), subsi\u00addiary of Scien\u00adti\u00adfic Indus\u00adtries, Inc. and deve\u00adlo\u00adper of opti\u00adcal sensors for non-inva\u00adsive real-time moni\u00adto\u00adring of cell culture systems, was divested.<\/p>\n
This ends a six-year invest\u00adment part\u00adner\u00adship that began in 2015 with the entry of Seed Fund II, the prede\u00adces\u00adsor of Tech\u00adVi\u00adsion Fund I, with a seven-figure invest\u00adment in the biotech\u00adno\u00adlogy company. \u201cIt is grati\u00adfy\u00ading that we can accom\u00adpany such a great foun\u00adding team to a successful exit with our early-stage funds. I look forward to seeing the success story of aquila biolabs conti\u00adnue along this path,\u201d says Dr. Ansgar Schlei\u00adcher, CEO of the S\u2011UBG Group.<\/p>\n
Expan\u00adding the plat\u00adfor\u00adm\u2019s reach worldwide \u201cWe are exci\u00adted to join SBI and expand the reach of our unique plat\u00adform to biopro\u00adcess scien\u00adtists around the world,\u201d says Daniel Gr\u00fcnes, co-foun\u00adder of aquila biolabs, who will assume the role of Vice Presi\u00addent of R&D and Opera\u00adti\u00adons at SBI. Jens Bayer, co-foun\u00adder of aquila biolabs, adds: \u201cWe would like to thank our inves\u00adtor consor\u00adtium once again for the very good and harmo\u00adnious coope\u00adra\u00adtion over the past years. Espe\u00adci\u00adally the enorm\u00adous wealth of expe\u00adri\u00adence of inves\u00adtors like Mr. Schu\u00adma\u00adcher and the Seed Fonds Aachen, who have frequently accom\u00adpa\u00adnied tech\u00adno\u00adlogy compa\u00adnies from the start-up phase to the exit, was very helpful for us.\u201d aquila biolabs will conti\u00adnue to offer its products and services around the globe from its head\u00adquar\u00adters in Baes\u00adwei\u00adler, where the company curr\u00adently employs 16 people.<\/p>\n SBI expands presence in Europe About the S\u2011UBG Group 2020, Tech\u00adVi\u00adsion Fonds I f\u00fcr die Region Aachen, Krefeld & M\u00f6nchen\u00adglad\u00adbach GmbH & Co. KG was laun\u00adched toge\u00adther with NRW.BANK, the savings banks of Aachen, Krefeld and D\u00fcren, Kreis\u00adspar\u00adkasse Heins\u00adberg, Stadt\u00adspar\u00adkasse M\u00f6nchen\u00adglad\u00adbach, Noma\u00adin\u00advest, DSA Invest GmbH, inves\u00adtors from the Dr. Babor Group and other private inves\u00adtors. It provi\u00addes around 40 million euros in seed capi\u00adtal for the start-up scene in the region. Tech\u00adVi\u00adsion Fonds I emer\u00adged from Seed Fonds III for the Aachen, Krefeld and M\u00f6nchen\u00adglad\u00adbach region. As an exten\u00adsion of Seed Fund III, Tech\u00adVi\u00adsion Fund I now seeks to parti\u00adci\u00adpate in subse\u00adquent finan\u00adcing rounds (Series A\/B) of exis\u00adting port\u00adfo\u00adlio compa\u00adnies in addi\u00adtion to seed invest\u00adments. The S\u2011UBG Group curr\u00adently holds stakes in just under 40 compa\u00adnies in the region, giving it a leading posi\u00adtion in the Spar\u00adkas\u00adsen-Finanz\u00adgruppe. www.s\u2011ubg.de; www.techvision-fonds.de<\/p>\n","protected":false},"excerpt":{"rendered":" Aachen \u2014 The \u201cSeed Fonds II f\u00fcr die Region Aachen GmbH & Co. KG\u201d (Seed Fonds Aachen), toge\u00adther with KfW Banken\u00adgruppe, Qiagen co-foun\u00ad\u00adder Dr. J\u00fcrgen Schu\u00adma\u00adcher and Dr. Robert Huber, Profes\u00adsor of Biopro\u00adcess Engi\u00adnee\u00adring, have sold their shares in the Aachen-based start-up aquila biolabs GmbH to Scien\u00adti\u00adfic Biopro\u00adces\u00adsing, Inc. (SBI), subsi\u00addiary of Scien\u00adti\u00adfic Indus\u00adtries, Inc. [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37336,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-43487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\n
\n<\/strong>
\nFoun\u00added in Aachen at the end of 2014, aquila biolabs GmbH deve\u00adlops a plat\u00adform of intel\u00adli\u00adgent sensors and soft\u00adware for the non-inva\u00adsive moni\u00adto\u00adring and analy\u00adsis of biopro\u00adces\u00adses in the labo\u00adra\u00adtory. With the help of the paten\u00adted measu\u00adre\u00adment methods, rese\u00adar\u00adchers can auto\u00adma\u00adti\u00adcally moni\u00adtor process para\u00adme\u00adters and observe the cells as they grow, without having to take samples. This signi\u00adfi\u00adcantly redu\u00adces deve\u00adlo\u00adp\u00adment times and costs and sustain\u00adably impro\u00adves biopro\u00adces\u00adses in acade\u00admic and indus\u00adtrial rese\u00adarch. The products of aquila biolabs GmbH are now used by custo\u00admers in the phar\u00admaceu\u00adti\u00adcal, biotech\u00adno\u00adlo\u00adgi\u00adcal and chemi\u00adcal indus\u00adtries in over 25 countries.<\/p>\n
\n<\/strong>
\n\u201cWhen SBI was explo\u00adring the available tech\u00adno\u00adlo\u00adgies that could drive digi\u00adtally simpli\u00adfied biopro\u00adces\u00adsing, aqui\u00adla\u2019s approach stood out as the most impres\u00adsive,\u201d said Rein\u00adhard Vogt, chair\u00adman of SBI and former vice presi\u00addent and member of the Sarto\u00adrius AG Execu\u00adtive Board. \u201cIn addi\u00adtion to offe\u00adring a broad range of advan\u00adced sensors and data analy\u00adtics tools, this stra\u00adte\u00adgic acqui\u00adsi\u00adtion also adds new talent to our strong team and streng\u00adthens our presence in Europe.\u201d<\/p>\n
\n<\/strong>
\nThe S\u2011UBG Group, Aachen, has been the leading part\u00adner in the provi\u00adsion of equity capi\u00adtal for estab\u00adlished medium-sized compa\u00adnies (S\u2011UBG AG) and young, tech\u00adno\u00adlogy-orien\u00adted start-ups (Tech\u00adVi\u00adsion Fonds I) in the econo\u00admic regi\u00adons of Aachen, Krefeld and M\u00f6nchen\u00adglad\u00adbach for over 30 years. S\u2011UBG AG invests in growth sectors; high quality of corpo\u00adrate manage\u00adment is a key invest\u00adment criter\u00adion for the invest\u00adment company.<\/p>\n